Category: ACN Newswire

SINGAPORE, Aug 16, 2025 - (ACN Newswire via SeaPRwire.com) - A 2022 survey from Vanson Bourne revealed that around 91%1 of respondents saw increased demand for automation from business teams. As AI technology evolves, that demand will only grow. AI automations can help organizations work smarter at every level. But how exactly do these workflows function? This article unpacks what AI workflow automation is and how it works behind the scenes.What is AI workflow automation?AI workflow automation is the use of artificial intelligence to automate complex, multi-step tasks that typically require human decision-making. While rule-based automation may rely on rigid instructions, AI automation adapts to data patterns. It learns over time and can flexibly handle unstructured input like emails, documents, or customer requests.AI workflow tools can understand, decide, and act based on context. These tools can help streamline processes and reduce manual effort while improving speed and accuracy.How do AI workflows function?AI workflows function by connecting a series of intelligent tasks or steps to complete a goal from start to finish. The specific tasks can vary depending on the use case. Some workflows may be entirely automated, while some may require human input. Let's take a closer look at some core components that power AI workflows.Machine learning (ML)Machine learning models can make predictions, identify problems, or find patterns. Machine learning has many uses in a workflow including classifying documents or prioritizing tasks. ML acts as the "decision engine", helping automate steps that would otherwise require manual analysis or classification.Natural language processing (NLP)NLP allows AI systems to understand and interpret human language for seamless communication. It's a crucial component in workflows that involve text, speech, or communication. For example, NLP can automatically extract key data from emails or summarize meeting notes. This enables organizations to automate content-heavy tasks without sacrificing understanding or context.Automation triggersAI workflows are usually event-driven. A trigger might be a form submission, a task status update, or an incoming message. Once initiated, the AI workflow executes a sequence of tasks based on logic, conditions, and model predictions. These triggers help organizations respond faster, reduce delays, and eliminate manual intervention.Predictive algorithmsPredictive AI models help forecast future outcomes based on past behavior. These algorithms can be used to detect workflow bottlenecks or even predict them based on past occurrences. Effective predictive models require good data and smart integration. When done right, they can help businesses make smarter, data-informed decisions with minimal human input.Benefits of AI workflowsHere are some of the advantages that AI workflows offer.Increased efficiency: Automations can take on repetitive and time-consuming tasks. This frees up teams to focus on more strategic work.Scalability: AI workflows can process large volumes of data or requests without extra headcount. They make it easier to scale services or operations.Improved accuracy: Trained models and rule-based logic may help reduce the risk of human error.Faster decision-making: AI workflows can analyze data and trigger decisions in real time. This may enable businesses to respond to problems or opportunities faster.From streamlining internal operations to powering real-time customer experiences, AI workflow automation is helping businesses scale their operations at a reduced cost. AI workflows offer a powerful path toward enhanced efficiency.[1] Vanson Bourne - Case studies Salesforce Business Demand for Automation. June 2022. https://www.vansonbourne.com/case-studies/business-demand-for-automation/CONTACT:Sonakshi MurzeManagersonakshi.murze@iquanti.comSOURCE: iQuanti Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年8月14日 - (亞太商訊 via SeaPRwire.com) - 越秀房地產投資信託基金（「越秀房產基金」，連同越秀房託資產管理有限公司，統稱「基金」；股份代號：405）公佈其截至2025年6月30日止六個月之中期業績。越秀房產基金管理團隊：主席及非執行董事江国雄先生（中）、執行董事及行政總裁區海晶女士（左）、財務總監關志輝先生（右）2025年中期業績摘要：- 整體經營穩定，收入總額為人民幣9.66億元（2024年同期：人民幣10.34億元）。- 於2025年6月30日，物業整體出租率為82.2%（2024年同期：84.0%）。- 平均融資成本為3.33%，較年初下降83個基點，剔除匯兌虧損的融資成本同比減少13.5%。- 中期分派每個基金單位約人民幣0.0333元，約等於0.0366港元。按年計算的分派收益率為8.42%。廣州國金中心：- 廣州國金中心綜合體錄得經營收入為人民幣4.86億元，佔基金收入總額50.3%。- 廣州國金中心寫字樓引進一家財富世界500強背景企業；出租率為82.6%；續約率為70%。- 國金天地期內出租率高達96.4%。- 廣州四季酒店平均入住率同比上升1.1個百分點，客房收入創歷史同期新高；國金中心雅詩閣服務式公寓平均入住率同比增長1.8個百分點，營業收入亦創歷史同期新高。廣州越秀金融大廈：- 越秀金融大廈錄得經營收入約人民幣1.65億元，佔基金收入17.1%，出租率達82.1%。- 租戶結構不斷優化，新引進優質租戶包括一家財富世界500強背景企業，以及一家市值超百億的期貨企業。積極管理融資風險，有效平抑融資成本- 針對2025年上半年到期的人民幣5.3億元短期貸款、21億港元5年期銀團貸款及今年內到期的其他貸款，管理人於2025年上半年完成人民幣5.3億元短期貸款續借，並通過取得人民幣17億元境外貸款和發行人民幣10億元點心債，用於到期貸款的再融資及提前置換，確保流動性風險得到有效管控。- 管理人期內合計引入人民幣32.3億元貸款，並置換境外浮息港元貸款，利用人民幣融資相對低位，主動調節融資結構，降低利率市場衝擊。2025年上半年末融資利率敞口約為14%，較年初26%收窄12個百分點；平均融資成本為3.33%，較年初4.16%下降83個基點；上半年平均付息率3.92%，同比下降64個基點。剔除匯兌虧損的融資成本約為人民幣4.02億元，同比減少13.5%。- 2025年6月末人民幣融資約147.95 億元，佔總體融資72%（2024年同期：人民幣融資約84.04 億元，佔總體融資41%）。越秀房產基金主席及非執行董事江国雄先生表示：「2025年上半年，在全球貿易環境波動及經濟增長放緩的背景下，中國國內生產總值GDP同比增長5.3%，但企業擴張保守緩慢；零售消費疲弱、酒店公寓房價承壓。為應對行業不利因素，我們策略性搶佔市場份額，提前推進續租工作，投入資本性改造，提升產品競爭力，有效穩住經營基本面，為中期經營收入提供堅實支撐。同時，融資成本回落也為分派創造有利條件。」國金中心國金中心透過提升產品和優化營運，客戶訪問量和轉化率均錄得正向提升，新簽13,133平方米。推出4,235平方米帶裝修單元去化週期僅約十九天，去化率接近九成。引進優質租戶包括一家財富世界500強背景企業、一家全球龍頭航運企業和一家知名互聯網背景文體娛樂企業，合計超過2,200平方米。續租9,099平方米，續租率70%，留存優質租戶包括兩家財富世界500強背景企業和一家外國領事館。國金中心入選觀點「表現力指數2025商辦資產運營表現」TOP30榜單。國金天地積極打造電子化消費場景，推進悅秀會本地生活平台試點落地，已覆蓋12家商戶，同時利用大眾點評、雲閃付等平台多渠道引流，新簽和續租合計5,734平方米，續租率97%。出租率為96.4%。期內，中免免稅店宣佈落戶國金天地，預計第三季度開業，成為廣州首家且目前唯一的市內免稅店。廣州四季酒店客房收入和國金中心雅詩閣服務式公寓營業收入分別創歷史同期新高。廣州四季酒店期內平均入住率為80.1%，同比上升1.1個百分點；平均房價為人民幣2,201元，與去年同期相若；每間可供出租客房收入(RevPAR)為人民幣1,762元，同比增長0.7%；RevPAR競爭指數為111.7，在奢華酒店競爭群組中始終保持較領先的市場地位。國金中心雅詩閣服務式公寓期內平均入住率為92.3%，同比上升1.8個百分點，平均入住率高於競爭群公寓9.7個百分點；平均房價為人民幣1,128元，與去年同期相若；RevPAR為人民幣1,041元，同比增長1.5%；RevPAR競爭指數達120.0。越秀金融大廈越秀金融大廈期內新簽7,448平方米，包括七家租戶擴租合計1,500平方米。推出7,089平方米帶裝修單元，去化週期約38天，去化率超過六成半。新引進優質租戶包括一家財富世界500強背景企業，以及一家市值超百億的期貨企業。受部分租戶回遷自有物業辦公的影響，續租10,303平方米，續租率42%。留存大面積優質租戶包括國際四大之一「德勤」和一家國內龍頭綜合性資產管理公司。白馬大廈白馬大廈引入珠三角供應鏈資源，期內帶動新簽3,273平方米，實現一樓滿租。上半年累計接待165個採批團，累計接待採購商近5,000人次，其中包括來自法國、越南等23個外商團，促成採購金額達人民幣1.4億元。白馬大廈依託大灣區國際女裝展、廣交會等展會促進租戶成交，亦成功推出「白馬悅境通」跨境電商平台和「白馬商學院營銷賦能營」系列課程，激活租戶數字化運營新動能。財富廣場財富廣場期內新簽2,354平方米，引進優質租戶包括一家財富世界500強綜合金融集團旗下醫療養老板塊的數家企業。續租2,924平方米，續租率76%，留存優質租戶包括一家財富世界500強背景企業，亦靈活匹配降本需求調整單元挽留租戶。城建大廈城建大廈期內新簽7,585平方米，引進一家美容科技企業提升樓內大健康業態氛圍。結合租戶降本意願制定挽留方案，優化產品標準匹配租戶需求。續租2,090平方米，續租率68%，包括一家全球知名合同研究組織(CRO)的廣州辦公室。維多利廣場維多利廣場期內主力租戶「優衣庫」繼續發揮旗艦作用，首發C系列產品，並於3月28日至4月6日落地全國首場「優衣庫美好生活市集」、巨型寶可夢及美好生活音樂活動，活動期間達季度客流峰值，帶動四月銷售額同比增長7%，推動中期期間銷售額同比增長0.3%。項目聯動餐飲租戶，抓住客流高峰提升銷售，帶動中期期間項目整體銷售額同比增長0.6%。上海越秀大廈上海越秀大廈期內續租3,798平方米，續租率39%；新簽3,933平方米，迅速填補退租單元。通過更換停車場節能燈管提升場內亮度，項目實現節能效益和服務水平雙提升，提高租戶滿意度。於中期期末，上海越秀大廈出租率為87.2%，同比增加2.6個百分點。武漢物業武漢越秀財富中心期內新簽12,395平方米，引進優質租戶包括一家全球領先汽車集團成員企業和一家多元化專業服務企業。續租10,884平方米，續租率81%，留存大面積優質租戶包括一家財富世界500強背景央企。招商團隊透過單元局部微改造、軟裝提升、打造智能樣板間等多種方式優化客戶看樓體驗，提升客戶轉化率。星匯維港購物中心期內新簽和續租合計3,894平方米，續租率82%。成功引進多家熱門餐飲品牌，包括A館一樓引進網紅品牌「達美樂」，帶動更多家庭客群。項目開拓夜間消費，利用四樓「悅花園」亮點優勢，持續打造「江畔星夜」、「深夜食堂」激發銷售新增長點。杭州維多利杭州維多利期內新簽1,974平方米，引進一家全層租戶。續租6,083平方米，續租率64%，留存優質租戶包括一家財富世界500強背景建築工程企業和一家山西省屬國企的浙江分公司。未來展望市場普遍憧憬美聯儲下半年進一步降息，但路徑和幅度仍具不確定性。另一方面，今年是中國「十四五」規劃收官之年，各項政策穩字當頭，包括適度寬鬆貨幣政策和「以舊換新」消費補貼政策，旨在通過擴大內需激發市場活力，因此管理人預期人民幣利率將維持較低水平。伴隨國內新質生產力加快培育發展和供給側改革深化推進，管理人預期產業動能繼續推陳出新，營商氣氛將向好改善。備受矚目的第十五屆全國運動會將於下半年在廣州開幕，有望帶動商場消費和酒店公寓需求。下半年，管理人將因應經濟發展走勢動態實施積極、穩健、靈活的租賃策略，敏銳把握潛在機會，持續提升資產組合市場競爭力。管理人將視市場發展預期對融資結構持續檢視並進行合理調整，通過各類人民幣融資途徑，引入低成本人民幣融資，以尋求更優融資成本，平滑利率風險。管理人將按計劃開展相關資本性改造工程，合理規劃和分段改造廣州四季酒店客房，圍繞產品提升、設備更新和安全保障維度，實現物業保值增值，為項目穩健經營保駕護航。關於越秀房地產投資信託基金越秀房地產投資信託基金（「越秀房產基金」）於2005年12月21日在香港聯交所上市，為全球首只投資於中國內地物業的上市房地產投資信託基金。越秀房產基金目前持有的物業組合包括位於廣州的廣州國際金融中心、白馬大廈、財富廣場、城建大廈、維多利廣場、越秀金融大廈、位於上海的越秀大廈、位於武漢的武漢物業（包括武漢越秀財富中心和星匯維港購物中心）、位於杭州的維多利商務中心以及位於香港的越秀大廈共10項高素質物業，物業產權面積共約118.4萬平方米，分別位於中國廣州市、上海市、武漢市、杭州市及香港市的核心商業區域。物業類型包括甲級寫字樓、商業綜合體、零售商業、酒店、服務式公寓、服裝專業市場等。傳媒查詢:縱橫財經公關顧問有限公司李惠兒電話: +852 2864 4834電郵：sprg_yx@sprg.com.hk梁家儀電話: +852 2114 4172張銘伊電話: +852 2864 4903網址:http://www.sprg.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年8月14日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀今日宣布，中國台灣地區藥政主管部門（TFDA）已正式受理維長寧（艾曲莫德，中國台灣地區商品名：「維長寧」）用於治療中重度活動性潰瘍性結腸炎（UC）患者的新藥上市許可申請（NDA）。這一進展標志著艾曲莫德繼在中國澳門、新加坡和中國香港獲批以及韓國NDA獲正式受理之後，在亞洲市場的准入取得又一重大里程碑。中國國家藥品監督管理局也於2024年12月正式受理艾曲莫德（維適平(R)）的新藥上市申請，預計將在今年年底或明年年初獲批。艾曲莫德是一款針對潰瘍性結腸炎，每日一次的口服一線治療藥物，能夠強效實現腸道黏膜愈合，且使用便捷，並具有良好的安全性特征。黏膜愈合是國內外潰瘍性結腸炎臨床指南一致認定的潰瘍性結腸炎治療目標。潰瘍性結腸炎患者盡早實現黏膜愈合，可大幅降低疾病複發率、住院率、結直腸切除手術率和結直腸癌發生風險。艾曲莫德已被納入2024年美國胃腸病學協會（AGA）臨床實踐指南, 推薦作為潰瘍性結腸炎的一線治療。2025年，艾曲莫德獲得2025年美國胃腸病學會（ACG）成人UC臨床指南的一線治療推薦，進一步印證了其全球專業共識下的臨床價值。雲頂新耀首席執行官羅永慶先生表示：「此次在中國台灣地區NDA申請的正式受理，是維長寧亞洲商業化進程中的又一重要進展。隨著亞洲地區潰瘍性結腸炎患者人數持續增長，臨床上存在巨大未滿足需求。僅在中國，2024年潰瘍性結腸炎患者數量約為80萬人，預計到2030年將達100萬人。患者面臨長期治療與生活質量的雙重挑戰。此次受理充分體現了對維長寧臨床價值的高度認可。我們將繼續加快這一創新療法在中國大陸及亞洲其他市場的上市進程，提升可及性，幫助患者實現長期疾病控制並改善生活質量。」本次申請基於ELEVATE UC III期注冊研究（ELEVATE UC 52和ELEVATE UC 12）和ENLIGHT研究（ES101002）的結果。ELEVATE UC III期注冊研究顯示，在既往常規治療、生物制劑或JAK抑制劑治療失敗或不耐受的中重度活動性潰瘍性結腸炎患者中，每日一次2mg艾曲莫德在第12周和第52周均顯示卓越且持久的臨床緩解和內鏡下深度黏膜愈合，且安全性良好，與既往研究一致。同時，ENLIGHT研究作為迄今最大規模的亞洲中重度UC III期注冊臨床研究，在中國大陸、中國台灣及韓國開展，共納入340名患者。研究結果顯示，艾曲莫德在誘導期和維持期均取得了顯著且具有統計學意義的療效優勢，為其在亞洲人群中的應用提供了有力證據支持。作為雲頂新耀在自身免疫性疾病領域的重磅產品，艾曲莫德已於2024年被納入粵港澳大灣區內地9市臨床急需進口港澳藥品醫療器械目錄，在大灣區先行使用，惠及UC患者，並成為公司第三款商業化新藥。今年3月，雲頂新耀已啟動艾曲莫德在嘉善工廠的本地化生產建設項目，以支持其在大中華區及亞洲其他市場的供應與商業化落地。 Copyright 2025 亞太商訊 via SeaPRwire.com.

阿聯酋拉斯海瑪市, 2025年8月14日 - (亞太商訊 via SeaPRwire.com) - 阿勒哈伊馬國際公司註冊中心（RAK ICC）宣布對其2019年《基金會條例》進行重大修訂，新規已於2025年7月31日生效。此次修訂是該制度自推出以來最為重要的更新之一，進一步鞏固了阿聯酋作為財富架構與長期資產保護競爭性司法管轄區的地位。RAK ICC基金會因其靈活性、保密性及法律穩健性而廣受認可，成為阿聯酋國內外高淨值人士、企業家及家族辦公室的首選架構工具。這類結構通常用於繼承規劃、家族治理，以及將多元化資產整合於單一法律實體之下。2025年的修訂引入了更強的法律保障及改進的治理措施，包括：1. 防火牆條款 —— 對與RAK ICC法規相衝突的外國判決提供更強有力的保護。2. 三年訴訟時效 —— 將對基金會設立或資產轉移提出異議的時限限制為三年。3. 訴因條款 —— 債權人欺詐索賠僅限於涉案的特定資產，且僅在該行為導致創辦人資不抵債時才適用。4. 脅迫與高管保護 —— 宣告在外國法律脅迫下採取的行為無效，從而保障基金會內部治理的自主權。5. 強化仲裁機制 —— 允許通過具備法院級權力的私下仲裁方式解決爭議。6. 私人受託基金會條款 —— 明確基金會作為受託人持有財產時的資產隔離及受信義務的完整性。RAK ICC基金會持有的資產現將享有更強的防火牆保護，確保與阿聯酋法律相衝突的外國判決無法對其執行。新規設立了三年的時效期，用於限制對基金會成立或資產轉入的質疑，為創辦人及受益人提供更大的確定性。改革還收緊了債權人保護規則，在欺詐性轉讓索賠中須證明創辦人資不抵債，並將責任限定在爭議資產的價值範圍內，以防涉及無關財產。此外，修訂後的法規著重維護治理完整性和營運韌性。基金會高管在收到與RAK ICC法律不一致的外國命令時，必須予以忽略，從而保障基金會決策的自主權。新框架明確規定，基金會作為受託人持有的信託財產在法律上獨立且與基金會自有財產分離，確保資產隔離的清晰性。爭議解決機制也得到了強化，擴大的仲裁條款賦予仲裁庭類似法院的權力，使爭議能夠高效、保密地解決，並符合國際最佳實踐。這些變化是RAK ICC維護前瞻性法律與監管環境整體戰略的一部分，旨在滿足全球標準的同時兼顧客群的特定需求。這也體現了該司法管轄區在支持兼顧控制、隱私與長期安全的高端財富規劃策略方面的承諾。透過強化其基金會制度，RAK ICC正鞏固其在阿聯酋的地位，成為尋求安全、靈活且符合國際合規標準的財富保全與跨代規劃解決方案的可信賴合作夥伴。關於RAK ICC阿勒哈伊馬國際公司註冊中心（Ras Al Khaimah International Corporate Centre，簡稱RAK ICC）是一家總部位於阿聯酋阿勒哈伊馬的公司註冊機構。該機構提供國際商業公司及基金會架構，通常用於私人及商業結構設計、資產整合以及繼承規劃。截至目前，RAK ICC已註冊成立數千家國際公司，並為數十億迪拉姆的結構化資產提供支持。其服務對象包括高淨值人士、企業家及尋求靈活、安全的長期商業與財富管理方案的企業。媒體諮詢請聯絡我們:Phone: +971 7 207 7177Email: info@rakicc.comWebsite: https://www.rakicc.com/contact-us/來源: RAK ICC Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年8月14日 - (亞太商訊 via SeaPRwire.com) - 中國辣味休閒食品行業龍頭企業，卫龙美味全球控股有限公司（「卫龙美味」或「集團」）及附屬公司（「集團」）（香港聯交所股票代碼：09985.HK）公佈截至2025年6月30日止六個月（「期內」）之中期業績。人民幣截至6月30日止六個月2025年2024年變動收入34.83億29.39億+18.5%毛利16.42億14.62億+12.3%毛利率47.2%49.8%-2.6個百分點期內淨利潤7.36億6.21億+18.5%淨利潤率21.1%21.1%保持穩定中期股息0.18元/普通股0.16元/普通股+12.5%2025年上半年，在全球消費增長普遍承壓下，中國消費市場依然是全球最大消費市場之一。得益於中國休閒食品市場近年來呈現出穩健的增長態勢，報告期內，卫龙美味緊跟行業發展趨勢，堅持多品類產品策略，聚焦創新，深度開展消費者洞察，精準捕捉市場需求，持續強化研發實力，並持續以年輕人喜愛的方式深化品牌滲透，通過各種線上線下的品牌活動搭建多維消費場景鏈接深化品牌滲透，持續推進全渠道覆蓋能力和銷售網絡，進而為客戶及消費者提供更好的服務和體驗。報告期內，卫龙美味經營策略成效彰顯，業績持續穩健攀升，收入與淨利潤均錄得雙位數增長。2025年上半年實現總收入34.83億元（人民幣，下同），同比增長18.5%，主要由於集團期內持續加強全渠道和品牌建設，並優化渠道結構。儘管報告期內部分原材料成本上漲導致集團毛利率由去年同期的49.8%下降2.6個百分點至47.2%，但在收入增長及集團積極提升供應鏈效率的共同因素驅動下，毛利仍同比增長12.3%至16.42億元。同時受惠於集團經營利潤的提升，集團期內凈利潤同比增長18.5%，至7.36億元；淨利潤率得以維持去年同期相同水平，為21.1%。基於期內整體績效表現，集團董事會決議派發2025年中期股息每股人民幣0.18元，派息比率約為60%，預計派付股息日期為2025年10月20日或前後。產品方面，集團堅持多品類產品策略，從新產品、新口味、新工藝、新包裝等維度發力，如拓展風味創新邊界，深度回應消費者對創新口味的需求。2025上半年，集團先後推出了麻醬口味「魔芋爽」和麻辣牛肉口味「親嘴燒」等多個新品，進一步拓展並豐富產品組合，提升產品品質，滿足市場多元化及個性化的消費需求，驅動產品力與市場需求匹配。品牌建設方面，集團持續以年輕人喜愛的方式深化品牌滲透，透過各種線上線下的品牌活動搭建多維消費場景鏈接，譬如聯合林里檸檬茶發起「爆辣挑戰」，憑藉爆款銷量與話題效應觸達更多消費者；攜手國潮品牌哭喊中心推出「大兒童專屬」系列，借節日營銷勾起青春味覺記憶。此外，集團於報告期內官宣王安宇擔任魔芋爽代言人，借力明星影響力拓寬傳播路徑。集團的一系列舉措有效觸達年輕客群，夯實了品牌年輕化與趣味化的發展根基。渠道方面，集團持續推進線下全渠道、線上全平台覆蓋策略。隨著各種新興渠道業態的興起，集團緊跟渠道變化，持續拓展終端網點，強化銷售團隊終端執行力，並聯合經銷商持續提升終端的服務能力和產品鋪市率，從而有力推動線下終端業績穩步增長。在線上領域，集團同樣積極佈局，構建全平台生態體系，確保與線下渠道形成有效聯動，助力全渠道發展戰略落地。此外，集團始終致力於生產設施的自動化升級與技術創新突破，同步加快各業務系統的數字化轉型進程。在此基礎上，集團不斷強化組織發展與核心人才梯隊建設，以此全面提升公司整體運營效能，為業務的持續穩健發展注入強勁動力。卫龙美味董事長劉衛平先生表示：「集團將始終堅守『多品類』產品策略，堅持產品創新，持續加碼品牌建設力度，不斷強化卫龙『年輕、有趣、有創意』的品牌形象與獨特調性。與此同時，集團積極擁抱變化，持續加強全渠道的覆蓋能力，為消費者提供更便捷的消費體驗。展望未來，集團將以更積極、更主動的心態擁抱市場的變化，以更好的產品、更優質的服務和體驗不斷提升我們的競爭力，持續為消費者、客戶、員工、投資人及社會創造更大的價值。」關於卫龙美味全球控股有限公司卫龙美味全球控股有限公司（「卫龙美味」）是中國領先的集研發、生產及銷售為一體的辣味休閒食品企業，擁有強勁的增長勢頭和頗具影響力的品牌。 卫龙美味以傳統美食為基礎開創了中國調味麵製品（俗稱「辣條」）行業，於2001年開創出第一根辣條，並引領了辣條行業標準建設。 憑藉出眾的品類拓展能力，本集團已成功擴展至蔬菜製品、豆製品及其它產品等品類，推出了包括魔芋爽、風吃海帶、小魔女等大單品。 卫龙美味是倍受中國年輕消費者喜愛的休閒食品品牌，擁有有效觸達年輕消費者的全渠道銷售及經銷網路。 如欲獲得更多資訊，請流覽： https：//www.weilongshipin.com/。 Copyright 2025 亞太商訊 via SeaPRwire.com.

SINGAPORE, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Artificial intelligence has many uses in daily life. From personalized shopping suggestions to voice assistants and real-time fraud detection, AI is working behind the scenes to make experiences smoother and more seamless. Behind every smart AI feature is a process that involves two distinct stages: AI training and AI inference. While they're both essential to building intelligent systems, they serve very different purposes and have unique requirements. Let's break down the differences between training and inference.What is AI training?AI training is the process of feeding an AI model large volumes of data, so it learns to recognize patterns and generate the required output.Training generally requires large volumes of labeled or unlabeled data, each of which may facilitate different forms of training.Labeled data: Some projects require a model to make decisions or generate output based on established patterns or correlations. Here, it makes sense to train the model on labeled data using supervised learning techniques.Unlabeled data: Training models on unlabeled data lets them detect new patterns and build an understanding of the relationships between inputs and outputs. This is called unsupervised learning.Think of AI training like teaching a student using flashcards, quizzes, and feedback. During training, the model constantly adjusts internal parameters (often millions or billions of them) to minimize errors and improve accuracy. This phase is computationally intensive and requires specialized hardware like GPUs or TPUs to process large datasets efficiently.For example, training an AI model to recognize objects in images might involve showing it millions of labeled photos of cats, cars, and coffee mugs until it can correctly identify these objects on its own.What is AI inference?Once a model has been trained, it's ready to perform tasks. AI inference is the process of using a trained model to make predictions or decisions on new, unseen data.Inference is typically faster and more lightweight than training. It's used in real-time applications like chatbots, recommendation engines, voice recognition, and edge devices like smartphones or smart cameras. Inference is the test of training. If the output or predictions from your model are inaccurate, you may need to go back to testing.Going back to the earlier example, inference is what happens when you upload a photo to your phone and the AI instantly recognizes your pet as a "cat." The model has been trained to recognize cat images; it just applies what it already knows.Where AI training and inference differThough both stages are part of the same AI lifecycle, they differ significantly in purpose, speed, and system requirements. Here's a closer look at the key differences:ObjectiveTraining aims to teach the AI model by exposing it to data and helping it learn relationships, rules, and patterns.Inference uses the trained model to generate output (such as predictions, classifications, or decisions) based on new data.Time takenTraining can take hours, days, or even weeks, depending on the size of the model and the complexity of the data. It's a resource-heavy, iterative process.Inference happens much faster, often in real time or near real time.Infrastructure needsTraining requires high-performance computing resources such as powerful GPUs or TPUs, and large memory bandwidth. Most training happens in cloud environments or specialized data centers.Inference can often run on lower-powered devices, including edge hardware like mobile phones or IoT devices. Dedicated inference servers or GPU instances may still be needed in some cases.AI training and inference work hand in hand, but they have different goals, requirements, and challenges. Training is about teaching the model, and inference is about putting it to work. Organizations planning AI projects must consider both phases when budgeting, selecting hardware, and choosing infrastructure.CONTACT:Sonakshi MurzeManagersonakshi.murze@iquanti.comSOURCE: OneMain Financial Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” or the “Group”, Stock Code: 1061.HK) is pleased to announce that a Biologics License Application (“BLA”) for EB12-20145P (HLX04-O), a recombinant anti-VEGF humanized monoclonal antibody injection, has recently been accepted by the Centre for Drug Evaluation (“CDE”) of the National Medical Products Administration (“NMPA”) in China. The product is jointly developed by the Group and Shanghai Henlius Biotech, Inc. (“Henlius”, Stock Code: 2696.HK) for the treatment of wet age-related macular degeneration (“wet-AMD”) in China.The phase 3 clinical trial of EB12-20145P (HLX04-O) among Chinese patients (“AURA-1”) has successfully reached the primary endpoint in April this year. AURA-1 is a multi-centre, randomised, double-blind, active-controlled, and non-inferiority phase 3 clinical trial which aimed to compare the efficacy and safety of EB12-20145P (HLX04-O) with that of ranibizumab administered by intravitreal injection (“IVT”) in newly diagnosed wet-AMD patients.In addition to AURA-1, the BLA of which has been validated by the NMPA, an international, multi-centre phase 3 clinical study of EB12-20145P (HLX04-O) in patients with wet-AMD is ongoing successively in several European countries, Australia, the United States, and China (“AURA-2”) with last patient last visit completed by January 2025. Moving forward, Essex will continue to strive for excellence by embracing innovation to develop first-in-class and best-in-class products, providing solutions for Tomorrow’s healthcare problems, Today.About wet-AMDAge-related macular degeneration (“AMD”) is one of the leading causes of visual impairment and blindness in the elderly worldwide [1]. According to the World Health Organization (WHO), about 30 million people have suffered from AMD globally, and about half a million people become blind due to AMD each year [2]. Wet age-related macular degeneration (“wet-AMD”) is characterised by the formation of subretinal choroidal neovascularization (CNV) and is responsible for approximately 90% of cases of AMD-related blindness. Due to an aging population, wet-AMD has become a serious social medical problem and indicated a huge burden of unmet need [3]. With the development of treatment for fundus diseases, anti-VEGF drugs are becoming the first-line therapy for the management of wet-AMD [4], and the efficacy and safety of vitreous injection of bevacizumab for wet-AMD have been verified in multiple clinical studies [5-11].About EssexEssex is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology.These products are marketed and sold through approximately 14,000 hospitals, supported by the Company’s 44 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, Essex maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications.Reference[1] 2020(1).[2] Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004 Nov;82(11):844-51.[3] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2): e106-116.[4] Li X R, Liu J P. Recognition of anti-VEGF therapy base on the mechanism of VEGF in wet age-related macular degeneration[J]. Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology, 2012, 30(4):289-292.[5] Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multi-centre randomized double masked study. BMJ. 2010 Jun 9;340:c2459.[6] Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897-908.[7] Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul;119(7):1399-411.[8] Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar -Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013 Nov;120(11):2300-9.[9] Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group. A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013 Mar;97(3):266-71.[10] Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146-52.[11] Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Peto T, Vingerling JR, Schlingemann RO. Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS One. 2016 May 20;11(5): e0153052. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - SGX Catalist-listed AsiaMedic Limited (the “Company” and, together with its subsidiaries, the “Group”) announced its unaudited financial results for the six months ended 30 June 2025 (“1H2025”), delivering 26% year-on-year revenue growth to S$16.6 million, up from S$13.2 million in 1H2024.This performance was led by the Group’s diagnostic imaging business, which contributed over 60% of total revenue, supported by strong demand at its flagship Shaw Centre clinic and contributions from the newly opened Novena imaging centre.Financial Highlights:Revenue up 26% to S$16.6 million, from S$13.2m in 1H2024, driven by strong growth in diagnostic imaging and steady performance in medical wellness.EBITDA attributable to owners of the Company was maintained at S$1.3 million, reflecting consistent contributions from core businesses, even as the new Novena centre incurred ramp-up losses.Net loss attributable to owners of the Company narrows significantly to S$38,603 from S$104,431 in 1H2024.Cash and cash equivalents stood at S$4.9 million, with an additional S$3.6 million in financial assets, reflecting strong underlying liquidity despite investments into Novena centre.Profitability was significantly affected by the new Novena imaging centre as it remains in its ramp-up phase. However, the Group’s financial performance reflects solid execution of its core business strategy amidst expansion.Mr Arifin Kwek (郭致宾), Chief Executive Officer of AsiaMedic Limited, said, “Our performance in the first half of 2025 reflects the continued strength of our diagnostic imaging business. Shaw Centre remained our primary growth engine with sustained patient volumes, while the newly opened Novena Centre, though still ramping up, has already begun contributing. These investments will further position us as a trusted provider of early detection and preventive care in Singapore.Our health screening and medical wellness segment remained stable, underpinned by the government awarded Grow Well SG programme and steady corporate wellness demand. While the opening of Novena has added to our cost, these are deliberate investments in capacity, technology, and skilled professionals in a key medical geographical location in Singapore, that position us for long term growth.We will continue to build on this foundation, focusing on scaling our imaging and health screening businesses while ensuring we deliver high quality, patient-centred care. With expanded capacity and prudent cost management, AsiaMedic is well placed to capture growth opportunities in Singapore’s healthcare sector.”As Singapore continues to position itself as a regional healthcare hub, AsiaMedic is well-placed to meet growing demand for accessible, high-quality diagnostic and preventive healthcare services. With established centres in Orchard and Novena — two of the country’s key medical precincts — the Group is strategically expanding its reach to serve a broader patient base. This geographic presence, supported by ongoing investments in technology, infrastructure, and clinical talent, positions AsiaMedic to play a meaningful role in advancing Singapore’s preventive care and early detection agenda.This media release should be read in conjunction with the financial statements announced on SGXNet.About AsiaMedic LimitedAsiaMedic Limited together with its subsidiaries (“AsiaMedic” or the “Group”) is a leading healthcare provider in Singapore which provides holistic solutions through integrated application of the latest medical technologies to preventand detect early illnesses to achieve positive experiences and clinical outcomes for patients. AsiaMedic is listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (SGX-ST).The Group is committed to helping clients through practical and personalised solutions delivered with the highestprofessional standards of service and expertise in a timely, safe and consistent manner.With convenient locations at Orchard and Novena, AsiaMedic is a preferred one-stop centre for:Diagnostic imaging and radiology servicesMedical wellness and health screening servicesPrimary healthcare servicesMedical aesthetic services and productsFor more information, please visit www.asiamedic.com.sgFor media and analysts’ queries, please contact:Waterbrooks ConsultantsWayne KooT: (65) 9338 8166 / (65) 8901 9780E: wayne.koo@waterbrooks.com.sg / query@waterbrooks.com.sgThis announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd. It has not been examinedor approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Pauline Sim (Registered Professional) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 6319 4954. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Following the lifting of the Black Rainstorm Warning Signal at 11:10am, the Food Expo, Beauty & Wellness Expo, Home Delights Expo, Food Expo PRO and Hong Kong International Tea Fair will reopen at 1:10pm.The Food Expo, Beauty & Wellness Expo, Home Delights Expo will be extended and close at 11pm from 15 August to 17 August, allowing public visitors to enjoy shopping in these fairs—with a single ticket. The Food Expo PRO and Hong Kong International Tea Fair will remain open until 6pm today and tomorrow (14 to 15 August) and until 5pm on Saturday (16 August), enabling trade buyers and exhibitors to continue their business discussions.Admission tickets valid for today may be used for entry on any of the remaining fair days.Sessions 2 and 3 of the International Conference of the Modernization of Chinese Medicine afternoon programme will be resumed in a hybrid format.HKTDC Food Expo PROfoodexpopro.hktdc.comHKTDC Hong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine (ICMCM)icmcm.hktdc.comMedia enquiriesOgilvy Public Relations:Rex Cheuk+852 5618 9908rex.cheuk@ogilvy.comDaisy Leung+852 9275 7704daisy.leung@ogilvy.comLeanne Pok+852 9379 9694leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley So+852 2584 4049stanley.hp.so@hktdc.orgSerena Cheung+852 2584 4272serena.hm.cheung@hktdc.orgClayton Lauw+852 2584 4472clayton.y.lauw@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - As the Black Rainstorm Warning Signal was issued at 7:50am, the opening of Food Expo, and the concurrent Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo and Home Delights Expo, will be postponed. The opening ceremony originally scheduled for 10:30am, is cancelled. The International Conference of the Modernization of Chinese Medicine will be accessible via livestream.The organiser will make appropriate arrangements to ensure the safety of those already at the venue and will closely monitor the weather conditions. The organiser will open the Food Expo, Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo and Home Delights Expo two hours after the Black Rainstorm Warning Signal is cancelled.HKTDC Food Expo PROfoodexpopro.hktdc.comHKTDC Hong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine (ICMCM)icmcm.hktdc.comMedia enquiriesOgilvy Public Relations:Rex Cheuk+852 5618 9908rex.cheuk@ogilvy.comDaisy Leung+852 9275 7704daisy.leung@ogilvy.comLeanne Pok+852 9379 9694leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley So+852 2584 4049stanley.hp.so@hktdc.orgSerena Cheung+852 2584 4272serena.hm.cheung@hktdc.orgClayton Lauw+852 2584 4472clayton.y.lauw@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on @hktdc and LinkedIn Copyright 2025 ACN Newswire via SeaPRwire.com.

東京, 2025年8月14日 - (亞太商訊 via SeaPRwire.com) - TANAKA PRECIOUS METAL GROUP Co., Ltd.（總公司：東京都中央區，執行總裁：田中 浩一朗）決定與株式會社JEPLAN（總公司：神奈川縣川崎市，代表取締役 社長兼執行總裁：高尾 正樹，以下稱「JEPLAN」）進行事業合作，旨在削減以產業用貴金屬展開事業的TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.於貴金屬回收製程的CO2排放，以及實現有機物的再資源化。此項舉措是由在貴金屬領域上持續努力實現循環經濟（Circular Economy）的TANAKA以及在塑膠領域上持續努力的JEPLAN協力合作，以實現脫碳和循環型社會為目標。TANAKA為實現循環型社會迄今所採取的舉措TANAKA自1885年創業以來，作為貴金屬業界的龍頭企業，長年致力於稀缺資源的貴金屬回收。特別是在接受客戶委託回收的製程廢棄物當中，本公司針對以有機物（塑膠）為主要成分且有貴金屬附著或吸附的製程廢棄物，迄今持續採用焚燒處理來去除有機物，並從剩餘的灰燼中回收貴金屬。在此焚燒處理中，雖然已針對去除環境管制物質進行應對，但要削減於燃燒有機物的過程中所產生的CO2，仍然是邁向實現脫碳社會的課題。透過與JEPLAN的事業合作而改變的貴金屬回收製程JEPLAN以一種稱作聚乙烯對苯二甲酸酯的塑膠為目標對象來建立獨家的化學回收技術。為了解決上述的CO2排放量課題，TANAKA藉由與JEPLAN的事業合作，正在研討除了過去採用焚燒處理的貴金屬回收製程以外，未來還可能利用化學回收處理。化學回收處理的目標對象估計是注射器、合成纖維擦拭布等塑膠。而在作為目標對象的貴金屬回收製程中CO2排放量預計可比過去抑制10%左右。另外，本製程不僅是回收貴金屬還可使塑膠再生，使TANAKA和JEPLAN在各自的專門領域中，為實現脫碳和循環型社會作出貢獻。株式會社JEPLAN總公司所在地：神奈川縣川崎市川崎區扇町12-2設立：2007年1月代表人：代表取締役 社長兼執行總裁 高尾 正樹主要事業內容：PET化學回收技術相關事業（目標對象：PET瓶、聚酯纖維）等官方網站：http://www.jeplan.co.jpJEPLAN提出以「讓所有物品進行循環使用」為使命，並以實現循環經濟為目標。以廢PET（PET瓶、聚酯纖維等）為目標對象，藉由使用獨家的PET化學回收技術分解至分子等級並去除雜質，使其重生轉變為具有與源自石油相同品質的再生素材。藉由使用使此獨家技術致力於回收，以實現循環使用有限的資源，也有助於削減CO2的排放量。關於TANAKATANAKA自1885年（明治18年）創業以來，營業範圍向來以貴金屬為中心，並以此展開廣泛活動。在日本國內，以最高水準的貴金屬交易量為傲的TANAKA，長年以來除了進行產業用貴金屬產品的製造和販售外，也供應貴金屬製作珠寶飾品和投資型貴金屬商品。本集團以貴金屬專業團隊之姿，旗下的國內外各集團公司協調合作，使製造、販售與技術一體化，並供應相關產品與服務。2024 年度（2024年12月止）的合併營業額為8,469億日圓，擁有5,591名員工。產業事業全球網站https://tanaka-preciousmetals.com產品諮詢表TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://tanaka-preciousmetals.com/tw/inquiries-on-industrial-products/新聞媒體諮詢處TANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/tw/inquiries-for-media/新聞稿: https://www.acnnewswire.com/docs/files/20250814_CT.pdf Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年8月14日 - (亞太商訊 via SeaPRwire.com) - 富衛集團有限公司（「富衛集團」或「富衛」）今天宣布了12項社區關愛撥款計劃，支援亞洲各地的本地社區，慶祝成立 12週年。自2013年成立以來，富衛集團從香港特別行政區、澳門特別行政區和泰國起步，現已擴展至亞洲共十個市場，包括柬埔寨、印尼、日本、馬來西亞、菲律賓、新加坡和越南。12項社區關愛撥款計劃將聚焦支持非政府機構，推動涵蓋理財素養、社會創業、就業準備及身心健康福祉等範疇的倡議。富衛集團行政總裁兼執行董事黃清風表示：「今年以新上市公司的身份慶祝富衛成立12週年，令這個里程碑更具意義。人壽保險業務極具個人化，而富衛現已服務亞洲三千萬客戶及其家庭。我們以『細心關懷』為核心價值之一，透過實質且有影響力的方式回饋社會，是實現我們為大眾創造保險新體驗此願景的重要實踐。」富衛集團於今年早前宣佈與JA（Junior Achievement）Worldwide延長合作夥伴關係。JA Worldwide是一家專注於青少年發展的慈善機構，也是 2025 年諾貝爾和平獎的提名機構。富衛與JA共同開發且屢獲殊榮的理財素養課程，預期到2027年底將惠及亞洲40,000多名學生。計劃的下一階段將透過推出全新教學工具，並與更多教師和家長攜手合作，加強於理財素養，心理健康和韌性的教育和知識。12項慈善機構撥款計劃包括：- 柬埔寨：與 Cambodia Children's Fund合作，推出「Let’s Save Debate」計劃，透過辯論與研究活動提升大學生的理財素養；- 香港：與青年成就香港部合作，進一步擴展「JA小財智．大夢想」課程，推出「JA SparktheDream同『理』．理財工作坊」，為小學生提供結合理財素養及社交情感學習的互動教育；支持睿動香港透過運動賦予青少年女性心理健康與自信；- 印尼：與 KUMPUL.ID 合作，支持「InnovateHer Academy 3.0」 計劃，為女性企業家提供商業技能培訓、導師指導及投資準備課程；與Prestasi Junior Indonesia合作，並借鑒 「JA小財智．大夢想」計劃的成功經驗，為30名學校教師提供技術培訓，讓他們能有效地為學生傳授理財素養課程；- 日本：與 NPO全國福祉理美容師養成協會（National Welfare Beauty and Barber Training Association）合作，在國際乳癌關注月向癌症患者提供醫療假髮及支援；- 馬來西亞：與GivingHub啟動「Bijak Ibu Jaga Anak & Kewangan （B.I.J.A.K. ）」計劃，為200個低收入家庭舉辦工作坊，推廣健康及理財素養，並提供200項健康篩查與諮詢服務；- 菲律賓：與Junior Achievement Philippines合作，通過「JA Forward Your Success」計劃協助應屆大學畢業生規劃財務與職業發展；- 新加坡：支持 Club Rainbow （Singapore） 的 「Ride and Walk for Rainbows 2025」 活動，為長期病患兒童及其家人提供支援，並安排罕見遺傳及神經疾病青少年參觀萬態野生動物世界 （Mandai Wildlife Reserve）；- 泰國：與Pimali Foundation合作資助七個酒店管理培訓獎學金，以協助弱勢青年建立可持續的職涯發展；與Junior Achievement Thailand合作，進一步擴展「JA小財智．大夢想」計劃，培訓30名教師，深化其理財素養技能以支援學生；- 越南：與 Startup Vietnam Foundation合作，支援「Be A Finnovator」計劃，舉辦大學生培訓及辯論比賽，培養金融知識、批判性思維與負責任的理財習慣。關於富衛集團富衛集團為泛亞洲人壽及健康保險公司，服務約三千萬名客戶，業務遍及亞洲十個市場，包括印尼人民銀行人壽保險（BRI Life）。富衛秉持以客為先的方針及科技賦能的模式，致力為客戶帶來創新定位、簡單易明的產品和簡單的保險體驗。自2013年成立以來，富衛於部分全球發展最迅速的保險市場營運業務，專注為大眾創造保險新體驗。富衛集團是香港聯合交易所有限公司主板上市的公司，股份代號為1828。如欲了解更多資訊，請瀏覽www.fwd.com Copyright 2025 亞太商訊 via SeaPRwire.com.

Kangji Medical Holdings Limited and Knight Bidco Limited today jointly announced the pre-conditional proposal for the privatisation of Kangji Medical Holdings Limited by way of a scheme of arrangement (the “Proposal”).Proposed privatisation of Kangji Medical Holdings LimitedThe Cancellation Price of HK$9.25 per share represents a 21.7% premium over the closing price on 30 June, 2025, being the Undisturbed Date, a 47.3% premium over the 360-trading day average closing price up to and including the Undisturbed Date, and exceeds the highest closing price as quoted on the Stock Exchange since 2022The proposed privatisation will be effected by way of a scheme of arrangement; the Offeror Concert Parties collectively hold 74.75% shares in the Company; an Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the ProposalThe Proposal presents shareholders with certainty over their ability to monetise their interests in Kangji Medical Holdings Limited, following a period of sustained pressure on trading prices and limited liquidityHONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Aug 12 2025, Kangji Medical Holdings Limited (“Kangji Medical” or the “Company”, Stock Code: 9997.HK) and Knight Bidco Limited (the “Offeror”) today jointly announced a privatisation proposal. The parties intend to implement the privatisation of the Company by way of a scheme of arrangement, with a view to enabling the Company to focus on long-term strategic decisions, such as longer-term business investment in R&D and operations enhancements.Upon completion of the Proposal, the Company will become a wholly-owned subsidiary of the Offeror, and the listing of the Shares will be withdrawn from the Stock Exchange.The Offeror is owned by a consortium comprising Mr. Zhong and Ms. Shentu (the Founders), the TPG Entities, NewQuest V and Al-Rayyan Holding. Rationale for the ProposalDue to the long-term underperformance in the trading prices and trading liquidity of the Shares, the ability of the Company to raise funds from the equity market has been significantly limited. In addition, the Company has to incur administrative, compliance and other listing related costs and expenses for maintaining the listing status. Accordingly, there are limited benefits for the Company to maintain its listing status.In light of intensifying competition in domestic market and ongoing regulatory uncertainties, and in order to achieve sustainable growth, the Company's long-term strategy requires significant investment which could create short-term pressure on the Company’s financial performance. It is anticipated that additional resources need to be allocated to areas including sales and marketing, investment in research, development, and commercialisation, and the Company’s market expansion outside of China.Considering this, and the listing-related costs, there are limited benefits for Kangji Medical to maintain its listing status. In addition, the implementation of the Proposal will alleviate pressure on Kangji Medical’s short-term financial performance, which enables better focus on strategic objectives. It is anticipated that additional resources will need to be allocated for its future sustainable growth.Furthermore, the Proposal provides minority shareholders an attractive opportunity to realise compelling returns amid market volatility, industry and macro uncertainties, and the limited liquidity of the Shares.Knight Bidco Limited’s proposal offers a timely solution to Kangji Medical and its shareholders. Its proposal to privatise Kangji Medical will:(a) reduce Kangji Medical’s administrative, compliance and other listing related costs;(b) relieve Kangji Medical from the pressure associated with short-term performance metrics and enable Kangji Medical to focus on long-term strategic decisions (such as longer-term investment in R&D and operations enhancements which might incur short-term losses); and(c) present shareholders with certainty over their ability to monetise their interests in Kangji Medical at an attractive premium to the undisturbed share price.In summary, the Offeror believes that a take-private transaction is the strategic alternative that provides immediate and most compelling value for all shareholders, while also avoiding exposure to uncertain market conditions.Overview of the ProposalThe proposal sets out a Cancellation Price of HK$9.25 per share, valuing the company at approximately US$1.4 billion on an equity value basis.[1]The Offeror has indicated the Cancellation Price is final and will not be increased further.The Cancellation Price reflects:A 21.7% premium over the closing price on the Undisturbed Date (being 30 June, 2025).A 47.3% premium over the closing price of 360-trading day average price up to and including the Undisturbed Date.An 84.6% premium over the 52-week closing low (HK$5.01) up to and including the Undisturbed Date.A Cancellation Price above the highest closing price as quoted on the Stock Exchange since 2022 (HK$8.66).The Cancellation Price has taken into account, among other things, the recent and historical prices of the Shares traded on the Stock Exchange, publicly available financial information of the Company and with reference to other similar privatisation transactions in Hong Kong in recent years.The Proposal is subject to satisfaction of the Pre-Conditions by the Pre-Condition Long Stop Date (being 31 January, 2026) and the Conditions by the Long Stop Date (being 30 April, 2026). The Company will appoint an independent financial adviser (the “IFA”) to advise the committee of directors who are considered independent for the purposes of the Proposal (the “Independent Directors”) for the purposes of making a recommendation to shareholders in connection with the Proposal. Details of the Proposal including the Independent Directors’ final recommendation on the Proposal and the IFA’s advice will be included in the Scheme Document, expected to be dispatched to shareholders in due course.Scheme MeetingDetails of the Scheme Meeting to be convened will be contained in the Scheme Document which is expected to be dispatched to shareholders in due course.There are several pre-conditions and conditions as set out in the Joint Announcement, including regulatory approvals, shareholders approval and compliance with other legislative requirements.Irrevocable UndertakingAn Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the Proposal. Further details are available in the Joint Announcement.Trading in the Shares of the Company has been suspended on the Stock Exchange since 9:00 a.m. on 18 July, 2025, pending the release of this Announcement. The Company has applied to the Stock Exchange for the resumption of trading of Shares with effect from 9 a.m. on August 13, 2025.J.P. Morgan acted as the exclusive financial advisor to the Offeror.Kangji Medical Holdings LimitedKangji Medical is a medical device group founded in 2004 with headquarters at Hangzhou, Zhejiang Province, China. It was listed at the mainboard of the Stock Exchange of Hong Kong in June 2020 (Stock Code: 9997.HK). The Company specializes in the design, development, manufacture and sale of minimally invasive surgery instruments and accessories (“MISIA”). It strives for the mission of “providing physicians with high-quality products and services, and dedicating to improve people’s health”. The Company offers a comprehensive product portfolio to provide physicians and hospitals one-stop and tailored surgical solutions primarily for four major surgical specialties, including obstetrics and gynecology, general surgery, urology, and thoracic surgery. It is also committed to developing an internationally recognized minimally invasive surgery instruments and accessories platform with global coverage.About Knight Bidco LimitedEach of the Offeror, MidCo and TopCo is a newly incorporated company in the Cayman Islands with limited liability and an investment holding company set up solely for the purposes of implementing the Proposal. As at the date of the announcement, the Offeror is wholly owned by MidCo, which in turn is wholly owned by TopCo. As at the date of this announcement, TopCo is held by the Consortium Members, as to approximately 25.53% by Fortune Spring ZM, approximately 14.47% by Fortune Spring YG, approximately 24.38% by TPG Asia VII, approximately 5.01% by Keyhole, approximately 5.69% by Knight Success, approximately 4.56% by NewQuest V and approximately 20.36% by Al-Rayyan Holding. As at the date of this announcement, save as disclosed in the section headed “Shareholding Structure of the Company” in the Joint Announcement, none of TPG Asia VII, Keyhole, Knight Success, NewQuest V and Al-Rayyan Holding is a Shareholder.Kangji Medical is controlled by Mr. Zhong and his spouse Ms. Shentu who together hold 52.98% of the shares in Kangji Medical. Following the privatisation of Kangji Medical, Mr. Zhong and Ms. Shentu will remain the largest shareholders in the ultimate parent company of the Offeror, holding 40.00% of the shares in TopCo via Fortune Spring ZM and Fortune Spring YG. Further details are available in the Joint Announcement.Each of the Founder Entities is a business company incorporated in the British Virgin Islands.Knight Success is a newly incorporated company in Singapore with limited liability and an investment holding company. Keyhole is an exempted company incorporated in the Cayman Islands with limited liability and an investment holding company. TPG Asia VII is a company incorporated in Singapore with limited liability. Each of Knight Success and Keyhole is either wholly owned or controlled by TPG Asia VII, which is in turn controlled by TPG Asia GenPar VII Advisors, Inc. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).TPG is a leading global alternative asset management firm founded in 1992 with more than US$269 billion of assets under management as of 30 June 2025. For many years, TPG has been investing in transformation, growth, and innovation and aims to build dynamic products and strategies for its investors while also instituting discipline and operational excellence across its investment strategies and performance of its portfolios.NewQuest V is a company incorporated in Singapore with limited liability and an investment holding company. NewQuest V is wholly owned by NewQuest Asia Fund V, L.P., which is in turn controlled by NewQuest Asia Fund V GP Ltd. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).Established in 2011, NewQuest is one of Asia’s leading secondary private equity platforms with the most experienced secondary team in Asia across five offices. Since its founding, NewQuest has focused on working with GPs to create bespoke, tailored solutions to meet liquidity and other strategic needs of private asset owners and their stakeholders. Starting from a strategic partnership forged in 2018, NewQuest became wholly owned by TPG in January 2022.Al-Rayyan Holding is a limited liability company established in 2012 under the regulations of the Qatar Financial Centre Authority in the State of Qatar, and is a 100%-owned indirect subsidiary of QIA, the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term outlook. As at the date of this announcement, Al-Rayyan Holding and its concert parties (other than those who are, or deemed to be, acting in concert with Al-Rayyan Holding solely in connection with the Consortium) are not interested in any Shares.For enquiries, please contact:Kangji Medical Holdings LimitedOfferorMedia contact: Wonderful Sky Financial Group LimitedAngie Li & Jason LaiTel: +852 6150 8598 / +852 9798 0715Email: po@wsfg.hkMedia contact: Brunswick GroupKatelin Stevenson & Tong Li+852 9875 3351 / +86 134 8872 6729TeamKnight@brunswickgroup.com[1] Based on HK$9.25 Cancellation Price per share, 1,207,994,000 shares outstanding, and USD/HKD of 7.85All capitalized terms which are used in this press release but not otherwise defined herein shall have the meanings ascribed to them in the Joint Announcement dated 12 August, 2025. This press release should be read in conjunction with the Joint Announcement, a copy of which is available on https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0812/2025081201338.pdf. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月13日 - (亞太商訊 via SeaPRwire.com) - 億勝生物科技有限公司（「億勝生物」或「集團」，股票代碼：1061.HK）欣然宣布，集團針對重組抗VEGF眼內注射液EB12-20145P（HLX04-O）的上市註冊申請（「BLA」）最近已被中國國家藥品監督管理局（「NMPA」）藥品審評中心（「CDE」）受理。該產品由集團與上海復宏漢霖生物技術股份有限公司（「復宏漢霖」，股票代碼：2696.HK）合作開發，用於治療濕性年齡相關性黃斑變性（wet age-related macular degeneration, 「wet-AMD」）。此注射液EB12-20145P（HLX04-O）在中國患者中開展的III期臨床研究（「AURA-1」）已於今年4月成功達到主要研究終點。AURA-1為一項多中心、隨機、雙盲、陽性對照的非劣效III期臨床研究，旨在比較EB12-20145P（HLX04-O）與雷珠單抗玻璃體內注射（IVT）治療新診斷的wet-AMD患者的有效性和安全性。除其BLA已獲NMPA受理申請的AURA-1外，EB12-20145P（HLX04-O）的一項國際多中心III期臨床研究（AURA-2）也在歐洲多個國家、澳大利亞、美國和中國順利開展，AURA-2最後一名患者的最後一次訪視已在2025年1月完成。未來，億勝生物將不懈追求卓越，擁抱創新，持續推動對同類首創(First-in-class)與同類最優(Best-in-class)產品的創新研發，以滿足未來更多的臨牀及商業化需求。關於濕性年齡相關性黃斑變性年齡相關性黃斑變性（AMD）是造成老年人視力損害和不可逆失明的主要原因之一[1]，根據世界衞生組織報告，全球約有3000萬AMD患者，每年約有50萬人因為AMD而致盲[2]。AMD致盲患者中，以脈絡膜新生血管（CNV）為特徵的濕性年齡相關性黃斑變性（wet-AMD）比例高達90%。隨着老年人口比例的不斷上升，wet-AMD已經成為一個日益嚴重的社會醫學問題，存在着巨大的未滿足的臨床需求[3]。隨着眼底治療方法的突破與發展，抗VEGF藥物已成為wet-AMD的一線療法[4]，貝伐珠單抗玻璃體腔注射治療wet-AMD的有效性和安全性也已在多項臨床研究中得到驗證[5-11]。關於億勝生物（股票代碼﹕1061.hk）億勝生物是一間專注於研發、生產和銷售基因工程藥物b-bFGF的生物製藥企業，擁有包括貝復舒(R)、貝復濟(R)、貝復新(R)在內的六種基因工程藥物在中國上市銷售。此外，公司還擁有包含一系列不含防腐劑單劑量滴眼液和適麗順(R)卵磷脂絡合碘膠囊等的多元化產品組合，主要應用於眼科及皮膚科處方藥領域的創傷修復及疾病治療。這些產品在公司於中國的44個區域辦事處的支持下，在逾14,000家醫院進行營銷和銷售。依託自身在生長因子和抗體技術領域的研發平台，億勝生物在多個臨床階段擁有強大的項目管線，涵蓋廣泛的領域和適應症。参考文献[1] 欧阳灵艺, 邢怡桥. 抗VEGF药物在湿性年龄相关性黄斑变性中的应用进展[J]. 国际眼科杂志, 2020(1).[2] Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004 Nov;82(11):844-51.[3] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2): e106-116.[4] Li X R, Liu J P. Recognition of anti-VEGF therapy base on the mechanism of VEGF in wet age-related macular degeneration[J]. Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology, 2012, 30(4):289-292.[5] Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multi-centre randomized double masked study. BMJ. 2010 Jun 9;340:c2459.[6] Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897-908.[7] Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul;119(7):1399-411.[8] Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar -Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013 Nov;120(11):2300-9.[9] Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group. A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013 Mar;97(3):266-71.[10] Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146-52.[11] Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Peto T, Vingerling JR, Schlingemann RO. Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS One. 2016 May 20;11(5): e0153052. Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月13日 - (亞太商訊 via SeaPRwire.com) - 2025年8月8日，全球知名指數公司MSCI公佈了最新一輪指數審議結果，潼關黃金（00340.HK）成功獲納入MSCI全球小型股指數（MSCI Global Small Cap Indexes）成份股，相關調整將於2025年8月26日收市後正式生效。躋身頂級指數，擁抱全球資本洪流MSCI指數是全球最具影響力的金融指數體系之一，被廣泛視為全球機構投資者的重要參考基準。據統計，目前全球追蹤MSCI指數的資金規模已超過17萬億美元，其中被動型基金規模達到2萬億美元。然而，MSCI全球小型股指數專注於篩選全球市場中業績亮眼、成長潛力突出的中小市值企業。該指數成份股篩選嚴格，調整機制靈活，能夠緊密跟蹤市場動態，成為眾多國際大型投資機構的投資參考依據。本次MSCI季度指數調整將於8月26日收盤後正式生效。根據過往調整經驗來看，臨近調整生效時，相關的指數基金、ETF以及以MSCI指數為參考的主動管理基金都將進入集中調倉階段，新增成份股的成交量會在調整前後顯著放大，股價波動性可能上升。從機構觀點來看，高盛維持對北亞（中國、日本、韓國）和部分週期性股票的增持評級，預計MSCI亞太指數未來12個月以美元計價的價格回報率為9%。以2025年5月MSCI指數調整為例，新晉成份股複宏漢霖（02696.HK）在生效後的累計漲幅超60%，充分體現了市場對指數納入效應的積極回饋。業績爆發式增長，夯實價值根基潼關黃金獲得MSCI青睞絕非偶然，其堅實的業績高增長提供了最強支撐。根據公司7月31日發佈的盈喜公告，2025年上半年，公司擁有人應占溢利預計將錄得約3.3-3.6億港元，同比大幅增長259%-291%。高速增長主要得益於兩大核心驅動因素：礦產黃金產量與銷量的顯著提升，以及報告期內礦產黃金平均銷售價格的上行。量價齊升的優異表現，展現公司卓越的運營能力與行業景氣度回升帶來的紅利。值得一提的是，MSCI在篩選成份股時，不僅關注當前業績，更獨具慧眼地發掘那些當前價值可能被市場部分忽視、但未來具備巨大上升空間的潛力企業。潼關黃金亮眼的盈利能力結合其在行業內的戰略佈局，完美契合了MSCI這一"價值發現者"的選股邏輯，其納入實至名歸。提升國際能見度，開啟價值重估與進階之路潼關黃金獲納入MSCI全球小型股指數，標誌著公司正式進入全球主流投資機構的視野，戰略意義深遠。此次納入將顯著拓寬國際投資者基礎，提升公司在資本市場的知名度與流動性。被動資金的配置需求與主動投資者的關注度提升，有望推動估值中樞上移，實現市值躍升的重要正向催化力量。尤為關鍵的是，此里程碑事件為公司未來爭取納入更重要的基準指數（如恒生指數系列）以及港股通資格奠定基礎，為潼關黃金描繪出進階更高層級資本市場的清晰路徑。未來，隨著潼關黃金在國際資本舞臺能見度的持續提升以及向恒生指數成份股等關鍵領域邁進的步伐，潼關黃金的資本市場故事，正翻開更具想像力的新篇章。黃金賽道上的這位"新貴"，其光芒正愈發璀璨。 Copyright 2025 亞太商訊 via SeaPRwire.com.

Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 13, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the resumption of work on the Environmental and Social Impact Assessment ("ESIA") for its 100%-owned Lac Knife flake graphite project located near Fermont, in the province's prolific iron ore mining district.The Company has formally re-engaged IOS Geosciences Inc. ("IOS"), a leading Québec-based geological consulting firm and former general contractor on the ESIA, to complete a total of sixteen (16) technical reports required for submission to Québec's environmental and natural resource authorities. These reports represent a major step in advancing the Lac Knife project toward permitting and the goal of mine construction.The ESIA program, initially launched in 2020, involves multidisciplinary technical evaluations and environmental baseline work conducted across 2020 and 2021. Finalization was delayed due to funding constraints but is now back on track. Report completion is estimated by early 2026, with submissions planned shortly thereafter to the Québec Ministry of Sustainable Development, Environment, and the Fight Against Climate Change ("MDDELCC"), as well as the Ministry of Natural Resources and Forests ("MRNF").The sixteen (16) technical reports in progress cover critical permitting areas, including:Condemnation and pit wall drillingAcid-generating potential analysisGeotechnical drilling and soil mechanicsSoil geochemistry and chemistry baselineLake-bottom geochemical and surface water quality surveysGroundwater habitat assessment and follow-upCaribou habitat assessment and follow-upGeometallurgical and graphite flake characterizationThese comprehensive studies are essential for satisfying Québec's rigorous environmental and social licensing requirements and underscore Focus Graphite's commitment to environmental stewardship and Indigenous engagement through project development.In parallel, Focus has also authorized IOS proceed with geochemical analysis of over 1,000 split and pulverized drill core samples collected from its 2022 exploration drilling program at the Lac Tétépisca ("Tétépisca") graphite project. The samples, targeting the Southwest MOGC and West Limb geophysical (MAG-EM) conductors, will undergo carbon and sulfur determinations at certified laboratories.Upon receipt of assays, IOS will finalize and submit the corresponding technical reports covering 14,900.5 metres of core drilling from 74 holes to the MRNF. An updated Canadian Institute of Mining, Metallurgy and Petroleum ("CIM") and National Instrument ("NI") 43-101 compliant Mineral Resource Estimate ("MRE") for the Manicouagan-Ouest Graphitic Corridor ("MOGC") graphite deposit is anticipated in Fall 2025, which will further define Tétépisca's development potential alongside Lac Knife."Resuming the ESIA is a pivotal milestone that moves us closer to full permitting and our goal of mine development at Lac Knife," said Dean Hanisch, CEO of Focus Graphite. "With most fieldwork and laboratory studies already complete, we're in a strong position to finalize this critical stage efficiently. At the same time, initiating assay work at Tétépisca to support an upgraded mineral resource estimate reflects our commitment to building value across our entire Québec asset base."The Company also announced the grant of incentive stock options as compensation to its directors, officers, employees, and consultants. Options to purchase up to 4,215,000 Common Shares of the Company have been granted at an exercise price of $0.14 per share. The options expire on 13 August, 2030. Additionally, the Company has granted 1,350,000 restricted stock units ("RSUs") to officers, directors, and consultants of the Company under the terms of the Company's restricted share unit and equity incentive plan (the "RSU and EIP Plan"). Each RSU entitles the holder to acquire one common share of the Company after the vesting period in accordance with the Plan.Qualified PersonsThe technical content disclosed in this news release was reviewed and approved by Réjean Girard, P.Geo. (QC), President of IOS Geosciences Inc., a consultant to the Company, and a qualified person as defined under National Instrument NI-43-101.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the completion and submission of the sixteen technical reports required for the Lac Knife Environmental and Social Impact Assessment, the anticipated timeline for ESIA report submission and permitting, the initiation and results of geochemical analyses at the Lac Tétépisca project, the anticipated updated NI 43-101 Mineral Resource Estimate for the Tétépisca deposit, the Company's positioning as a near- and long-term secure supplier of specialty graphite materials, and the potential geopolitical significance of Canadian graphite supply.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262450 Copyright 2025 ACN Newswire via SeaPRwire.com.

ROMEOVILLE, IL, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, has signed an agreement with Syensqo to distribute its Solef® Polyvinylidene Fluoride (PVDF) materials in North America. The agreement expands access to this critical material known for its combination of chemical resistance and flexibility. Solef® PVDF joins a growing list of high-performance materials in Formerra's portfolio designed to advance product development and innovation."With this new agreement, Formerra will be able to support customers across multiple markets with the materials they need to meet demanding application requirements," said Bob Long, Business Development Manager at Formerra. "In addition, this reinforces our commitment to delivering unmatched access, application support, and advanced materials for customers navigating complex performance and regulatory challenges."PVDF is positioned near the top of the performance pyramid for its outstanding chemical and heat resistance. Its inherent flexibility further enhances its suitability for demanding applications in chemical processing, healthcare, and automotive industries. Key properties* include:Heat resistance: Continuous use temperatures up to 150 degrees C (302 degrees F), bursting pressures of up to 139 bar (2,017 psi) at room temperatureChemical purity: Ultra-pure water resistivity, meeting SEMI F-57 specifications for the semiconductor industryBalance of strength and flexibility: Tensile yield strength up to 55 MPa (8,000 psi) with elongation at break up to 100%"We chose Formerra as our distribution partner for Solef® PVDF in North America because of their technical and commercial reach," said Rose Catherin, Sales Director Americas, Channel partners, Distribution and Digital Sales at Syensqo Specialty Polymers. "Their commitment to excellence and long-standing presence in critical markets make them an ideal fit to help expand the availability and use of Solef® PVDF."*As measured by TDSCaption: Formerra Becomes North American Distributor for Syensqo Solef®PVDF.Key Details:Formerra is an authorized distributor of Solef® PVDF from Syensqo in North America.The agreement includes support for high-performance applications across a broad spectrum of industries.PVDF offers excellent chemical resistance, thermal stability, and flexibility.Formerra provides technical guidance and supply chain expertise to support material selection and application development.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2025 ACN Newswire via SeaPRwire.com.

WESTLAKE, OH, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - GEON® Performance Solutions, a global leader in the formulation, development and manufacture of performance polymer solutions, announced today that it received Great Place To Work® (GPTW) certifications for its USA, Canada, Mexico and China locations. Since partnering with GPTW in 2021, GEON's cultural and sustainability vision is to achieve this recognition each year.GPTW Certified GEON is Great Place to Work-Certified in the US, Canada, Mexico and China.GPTW asks employees to quantify and benchmark their experience, workplace culture and leadership behaviors which are proven to deliver market-leading revenue, employee retention and increased innovation."We are thrilled to receive Great Place To Work recognition in all four countries in which we operate for two consecutive years. Great Place To Work companies are evaluated against top employers globally, so this is a testament that our journey to cultural excellence is on the right track," said GEON Chief Executive Officer Tracy Garrison. "We believe leaders in the marketplace must also be leaders in the workplace. To do this, we nurture a positive work culture everywhere we operate while striving to grow in areas that still need improvement."GEON received a 79 percent engagement rating which exceeds the typical company by over 20 percent. GEON's score improved year-over-year in the U.S., Canada and China and held steady in Mexico. The U.S. survey included the full scope of GEON employees, including employees from Foster, LLC which GEON acquired in January of 2025.According to Great Place To Work research, job seekers are 4.5 times more likely to find a great boss at a Certified™ great workplace. Additionally, employees at Certified workplaces are 93 percent more likely to look forward to coming to work and are twice as likely to be paid fairly and have a fair chance at promotion."Like the data show, achieving GPTW certification is not only a reflection of our culture, but it directly impacts our ability to retain good people who are excited to come to work each day," said GEON Chief Human Resources Officer Jerome Beguerie. "This has a direct impact on our customers and their experience with us."About GEON Performance SolutionsGEON® Performance Solutions is a leading innovator in the development of polymer compounding solutions for a broad range of markets including building & infrastructure, consumer, industrial, transportation, and power & communications. With the acquisition of Foster, LLC, GEON has enhanced participation in the high-growth healthcare and medical device industry and builds on a portfolio of highly adaptable vinyl, polyolefin and engineered resin technologies as well as a full-service contract manufacturing business. GEON has approximately 1,200 global associates and 15 world-class manufacturing plants with headquarters in Westlake, Ohio. Learn more at www.geon.com. GEON is a portfolio company of SK Capital Partners.About SK CapitalSK Capital is a transformational private investment firm with a disciplined focus on the specialty materials, ingredients, and life sciences sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital currently has approximately $10 billion in assets under management as of December 31, 2024. For more information, please visit www.skcapitalpartners.com.Contact InformationRenita AndersonVice President, Marketing & Business Developmentrenita.anderson@geon.com678-772-8953SOURCE: GEON Performance Solutions Copyright 2025 ACN Newswire via SeaPRwire.com.